The stock is trading as a merger-arbitrage vehicle with no standalone operating value. Monitor for the closing of the Eos SENOLYTIX merger, which is the sole catalyst. The S-3 shelf registration for resale of shares by the Eos affiliate adds potential overhang post-merger.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $1.51entry
- T+1 · 3mo ago +1.99%α +2.18% · $1.54
- T+5 · 3mo ago −0.66%α +1.30% · $1.50
- T+20 · 2mo ago −6.62%α −4.88% · $1.41
- T+60 · 11d ago −8.61%α −3.13% · $1.38
Price Chart
How similar events traded
Executive Summary
Pulmatrix reported Q2 2026 financial results, showing a net loss of $1.036M ($0.29/share) compared to a $1.549M loss ($0.42/share) in Q2 2025, driven by reduced G&A expenses. The company has no revenue and is a pre-reverse-merger shell, with cash burn reducing its cash position to $2.2M (plus $0.7M restricted). The filing is a procedural update on the pending merger with Eos SENOLYTIX, which is expected to close in Q3 2026, and the company continues to operate as a going concern only through that closing.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $1.036M, improved from $1.549M in Q2 2025.
- Cash and cash equivalents fell to $2.2M at June 30, 2026, from $4.1M at December 31, 2025.
- The company has no revenue and all clinical development is on hold.
- The merger with Eos SENOLYTIX is expected to close in Q3 2026; an S-4 registration statement has been filed.
- Financial statements are prepared on a going-concern basis, with cash sufficient only through the anticipated merger close.
Financial Impact
Cash burn of ~$1.9M in H1 2026; no revenue; merger-dependent solvency
Risk Factors
- Merger fails to close, leading to cash depletion and potential bankruptcy.
- Post-merger dilution: current PULM stockholders will own only ~6% of the combined entity.
- S-3 registration enables immediate selling by the Eos affiliate post-merger, creating overhang.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037592 |
| Document: form8-k.htm | 0001493152-26-037592 |
| Document: 0001493152-26-037592-index-headers.html | 0001493152-26-037592 |
| Document: 0001493152-26-037592-index.html | 0001493152-26-037592 |
| Document: 0001493152-26-037592.txt | 0001493152-26-037592 |
| 8-K Data (Synthetic) | 0001493152-26-037592 |
Track record
21 reports on PULM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
- Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
- Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
- Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
- Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
- Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
- Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers